These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 27322078)
21. Realgar-indigo naturalis formula for the treatment of patients with relapsed and arsenic trioxide-resistant acute promyelocytic leukemia: A case series. Fang YG; Huang SL; Chen NN J Integr Med; 2024 Sep; 22(5):614-620. PubMed ID: 39183097 [TBL] [Abstract][Full Text] [Related]
22. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. Jiang H; Liang GW; Huang XJ; Jiang Q; Han S; Shi LW; Zhu HH Leuk Res; 2015 Dec; 39(12):1319-24. PubMed ID: 26403986 [TBL] [Abstract][Full Text] [Related]
23. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status. Xu LW; Su YZ; Tao HF Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421 [TBL] [Abstract][Full Text] [Related]
24. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821 [TBL] [Abstract][Full Text] [Related]
25. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia. Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675 [TBL] [Abstract][Full Text] [Related]
26. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Chen L; Wang J; Hu X; Xu X Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286 [TBL] [Abstract][Full Text] [Related]
27. Induction treatments for acute promyelocytic leukemia: a network meta-analysis. Huang J; Sun M; Wang Z; Zhang Q; Lou J; Cai Y; Chen W; Du X Oncotarget; 2016 Nov; 7(44):71974-71986. PubMed ID: 27713127 [TBL] [Abstract][Full Text] [Related]
28. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687 [TBL] [Abstract][Full Text] [Related]
29. Highly Curative Treatment of High-Risk Acute Promyelocytic Leukemia: Induction and Consolidation with ATRA+ATO+anthracyclines and Maintenance with ATRA+RIF. Liu D; Tong J; Chen E; Wang L; Xue L; Zhang X; Zhao N; Hu X; Zheng C Blood Lymphat Cancer; 2024; 14():63-69. PubMed ID: 39100972 [TBL] [Abstract][Full Text] [Related]
30. Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). Chen L; Zhu HM; Li Y; Liu QF; Hu Y; Zhou JF; Jin J; Hu JD; Liu T; Wu DP; Chen JP; Lai YR; Wang JX; Li J; Li JY; Du X; Wang X; Yang MZ; Yan JS; Ouyang GF; Liu L; Hou M; Huang XJ; Yan XJ; Xu D; Li WM; Li DJ; Lou YJ; Wu ZJ; Niu T; Wang Y; Li XY; You JH; Zhao HJ; Chen Y; Shen Y; Chen QS; Chen Y; Li J; Wang BS; Zhao WL; Mi JQ; Wang KK; Hu J; Chen Z; Chen SJ; Li JM Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33495363 [TBL] [Abstract][Full Text] [Related]
31. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). Wang HY; Gong S; Li GH; Yao YZ; Zheng YS; Lu XH; Wei SH; Qin WW; Liu HB; Wang MC; Xi JY; Chen LM; Zhang M; Zhang XX; Zhang HY; Zhang CS; Wald DN; Zhu HH; Liu L; He PC Blood Cancer J; 2022 Nov; 12(11):158. PubMed ID: 36404343 [TBL] [Abstract][Full Text] [Related]
32. Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Kayser S; Krzykalla J; Elliott MA; Norsworthy K; Gonzales P; Hills RK; Baer MR; Ráčil Z; Mayer J; Novak J; Žák P; Szotkowski T; Grimwade D; Russell NH; Walter RB; Estey EH; Westermann J; Görner M; Benner A; Krämer A; Smith BD; Burnett AK; Thiede C; Röllig C; Ho AD; Ehninger G; Schlenk RF; Tallman MS; Levis MJ; Platzbecker U Leukemia; 2017 Nov; 31(11):2347-2354. PubMed ID: 28322237 [TBL] [Abstract][Full Text] [Related]
33. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia. Long ZJ; Hu Y; Li XD; He Y; Xiao RZ; Fang ZG; Wang DN; Liu JJ; Yan JS; Huang RW; Lin DJ; Liu Q PLoS One; 2014; 9(8):e104610. PubMed ID: 25122165 [TBL] [Abstract][Full Text] [Related]
34. Role of arsenic trioxide in acute promyelocytic leukemia. Iland HJ; Seymour JF Curr Treat Options Oncol; 2013 Jun; 14(2):170-84. PubMed ID: 23322117 [TBL] [Abstract][Full Text] [Related]
35. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Kutny MA; Geyer S; Laumann KM; Gregory J; Willman CL; Stock W; Larson RA; Powell BL; Feusner JH Pediatr Blood Cancer; 2019 Mar; 66(3):e27542. PubMed ID: 30393935 [TBL] [Abstract][Full Text] [Related]
36. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819 [TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. Lachaine J; Mathurin K; Barakat S; Couban S Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894 [TBL] [Abstract][Full Text] [Related]
38. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission. Muchtar E; Vidal L; Ram R; Gafter-Gvili A; Shpilberg O; Raanani P Cochrane Database Syst Rev; 2013 Mar; (3):CD009594. PubMed ID: 23543579 [TBL] [Abstract][Full Text] [Related]
39. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. Zhu HH; Guo ZP; Jia JS; Jiang Q; Jiang H; Huang XJ Leuk Res; 2018 Feb; 65():14-19. PubMed ID: 29232592 [TBL] [Abstract][Full Text] [Related]
40. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide. Jung YS; Cheong HJ; Kim SJ; Kim KH; Lee N; Park HS; Won JH Leuk Res; 2014 Aug; 38(8):977-82. PubMed ID: 24953245 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]